245 related articles for article (PubMed ID: 36350986)
1. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion.
Jung IY; Narayan V; McDonald S; Rech AJ; Bartoszek R; Hong G; Davis MM; Xu J; Boesteanu AC; Barber-Rotenberg JS; Plesa G; Lacey SF; Jadlowsky JK; Siegel DL; Hammill DM; Cho-Park PF; Berger SL; Haas NB; Fraietta JA
Sci Transl Med; 2022 Nov; 14(670):eabn7336. PubMed ID: 36350986
[TBL] [Abstract][Full Text] [Related]
2. NR4A transcription factors limit CAR T cell function in solid tumours.
Chen J; López-Moyado IF; Seo H; Lio CJ; Hempleman LJ; Sekiya T; Yoshimura A; Scott-Browne JP; Rao A
Nature; 2019 Mar; 567(7749):530-534. PubMed ID: 30814732
[TBL] [Abstract][Full Text] [Related]
3. Nr4a1 and Nr4a3 Reporter Mice Are Differentially Sensitive to T Cell Receptor Signal Strength and Duration.
Jennings E; Elliot TAE; Thawait N; Kanabar S; Yam-Puc JC; Ono M; Toellner KM; Wraith DC; Anderson G; Bending D
Cell Rep; 2020 Nov; 33(5):108328. PubMed ID: 33147449
[TBL] [Abstract][Full Text] [Related]
4. Deletion of Cbl-b inhibits CD8
Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
[TBL] [Abstract][Full Text] [Related]
5. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells.
Seo H; González-Avalos E; Zhang W; Ramchandani P; Yang C; Lio CJ; Rao A; Hogan PG
Nat Immunol; 2021 Aug; 22(8):983-995. PubMed ID: 34282330
[TBL] [Abstract][Full Text] [Related]
6. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8
Seo H; Chen J; González-Avalos E; Samaniego-Castruita D; Das A; Wang YH; López-Moyado IF; Georges RO; Zhang W; Onodera A; Wu CJ; Lu LF; Hogan PG; Bhandoola A; Rao A
Proc Natl Acad Sci U S A; 2019 Jun; 116(25):12410-12415. PubMed ID: 31152140
[TBL] [Abstract][Full Text] [Related]
7. Early programming of CD8
Odagiu L; Boulet S; Maurice De Sousa D; Daudelin JF; Nicolas S; Labrecque N
Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24392-24402. PubMed ID: 32913051
[TBL] [Abstract][Full Text] [Related]
8. Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy.
Yoshikawa T; Wu Z; Inoue S; Kasuya H; Matsushita H; Takahashi Y; Kuroda H; Hosoda W; Suzuki S; Kagoya Y
Blood; 2022 Apr; 139(14):2156-2172. PubMed ID: 34861037
[TBL] [Abstract][Full Text] [Related]
9. Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells.
Zhao S; Wang C; Lu P; Lou Y; Liu H; Wang T; Yang S; Bao Z; Han L; Liang X; Ma C; Gao L
J Immunother Cancer; 2021 Nov; 9(12):. PubMed ID: 34853180
[TBL] [Abstract][Full Text] [Related]
10. CD19 CAR T cell product and disease attributes predict leukemia remission durability.
Finney OC; Brakke HM; Rawlings-Rhea S; Hicks R; Doolittle D; Lopez M; Futrell RB; Orentas RJ; Li D; Gardner RA; Jensen MC
J Clin Invest; 2019 May; 129(5):2123-2132. PubMed ID: 30860496
[TBL] [Abstract][Full Text] [Related]
11. Progressively Enhancing Stemness of Adoptively Transferred T Cells with PI3Kδ Blockade Improves Metabolism and Antitumor Immunity.
Rangel Rivera GO; Dwyer CJ; Knochelmann HM; Smith AS; Aksoy BA; Cole AC; Wyatt MM; Kumaresan S; Thaxton JE; Lesinski GB; Paulos CM
Cancer Res; 2024 Jan; 84(1):69-83. PubMed ID: 37801615
[TBL] [Abstract][Full Text] [Related]
12. An NK-like CAR T cell transition in CAR T cell dysfunction.
Good CR; Aznar MA; Kuramitsu S; Samareh P; Agarwal S; Donahue G; Ishiyama K; Wellhausen N; Rennels AK; Ma Y; Tian L; Guedan S; Alexander KA; Zhang Z; Rommel PC; Singh N; Glastad KM; Richardson MW; Watanabe K; Tanyi JL; O'Hara MH; Ruella M; Lacey SF; Moon EK; Schuster SJ; Albelda SM; Lanier LL; Young RM; Berger SL; June CH
Cell; 2021 Dec; 184(25):6081-6100.e26. PubMed ID: 34861191
[TBL] [Abstract][Full Text] [Related]
13. Deletion of the protein tyrosine phosphatase PTPN22 for adoptive T cell therapy facilitates CTL effector function but promotes T cell exhaustion.
Teagle AR; Castro-Sanchez P; Brownlie RJ; Logan N; Kapoor SS; Wright D; Salmond RJ; Zamoyska R
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056892
[TBL] [Abstract][Full Text] [Related]
14. BCL6 promotes a stem-like CD8
Sun Q; Cai D; Liu D; Zhao X; Li R; Xu W; Xie B; Gou M; Wei K; Li Y; Huang J; Chi X; Wei P; Hao J; Guo X; Pan B; Fu Y; Ni L; Dong C
Sci Immunol; 2023 Oct; 8(88):eadh1306. PubMed ID: 37862431
[TBL] [Abstract][Full Text] [Related]
15. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity.
Prinzing B; Zebley CC; Petersen CT; Fan Y; Anido AA; Yi Z; Nguyen P; Houke H; Bell M; Haydar D; Brown C; Boi SK; Alli S; Crawford JC; Riberdy JM; Park JJ; Zhou S; Velasquez MP; DeRenzo C; Lazzarotto CR; Tsai SQ; Vogel P; Pruett-Miller SM; Langfitt DM; Gottschalk S; Youngblood B; Krenciute G
Sci Transl Med; 2021 Nov; 13(620):eabh0272. PubMed ID: 34788079
[TBL] [Abstract][Full Text] [Related]
16. BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia.
Zhong M; Gao R; Zhao R; Huang Y; Chen C; Li K; Yu X; Nie D; Chen Z; Liu X; Liu Z; Chen S; Lu Y; Yu Z; Wang L; Li P; Zeng C; Li Y
Cell Death Dis; 2022 Aug; 13(8):671. PubMed ID: 35918330
[TBL] [Abstract][Full Text] [Related]
17. Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion.
Lamarche C; Ward-Hartstonge K; Mi T; Lin DTS; Huang Q; Brown A; Edwards K; Novakovsky GE; Qi CN; Kobor MS; Zebley CC; Weber EW; Mackall CL; Levings MK
Proc Natl Acad Sci U S A; 2023 Apr; 120(14):e2219086120. PubMed ID: 36972454
[TBL] [Abstract][Full Text] [Related]
18. Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function.
Blaeschke F; Ortner E; Stenger D; Mahdawi J; Apfelbeck A; Habjan N; Weißer T; Kaeuferle T; Willier S; Kobold S; Feuchtinger T
Front Immunol; 2022; 13():845499. PubMed ID: 35464394
[TBL] [Abstract][Full Text] [Related]
19. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
[TBL] [Abstract][Full Text] [Related]
20.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
